Research

The Richmond Research Institute is an independent, not-for-profit, academic research unit dedicated to clinical trial safety optimisation. Our studies help to improve the health and safety of patients taking part in clinical trials.

Randomised control trials

We investigate the health effects of interventions.

We perform studies on defined clinical groups.

We gather information from large datasets to obtain health-related insights.

Cohort studies

Big data analytical studies

Current studies

12.061: Type I diabetes monitoring and QTc interval.

Diabetes mellitus (DM) is a common metabolic disorder characterised by high blood glucose. It is caused by a lack of pancreatic beta-cell insulin production in type 1 DM. Patients with type 1 diabetes mellitus have a seven-fold higher risk of sudden cardiac death than age-matched nondiabetic controls, although the underlying mechanism for this is unclear. Sudden cardiac death is closely linked with cardiac arrhythmia, particularly Torsades de Points (TdP) and prolongation of the QT interval is a key risk factor.

Related Publications

Text Link

21.026: Telemonitoring in cardiac amyloidosis (PATHWAY-RCT).

Cardiac amyloidosis is a condition where the heart muscle, amongst other tissues, is infiltrated by the abnormal build-up of proteins called amyloid. This stiffens and thickens the heart muscle over time which makes it less efficient and puts further stress and strain on the other chambers of the heart, leading to heart failure. Telemonitoring is the practice of monitoring patients from a distance and has been shown to reduce heart failure admissions and death in patients with heart failure from any cause. This prospective clinical study monitors the weight, the most reliable clinical sign of this fluid build-up, of patients with cardiac amyloidosis at home and intervene where a build-up of fluid is observed by telephone discussion with a doctor. This study will evaluate the effect fairly by comparing telemonitoring with usual care.